Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.36 |
| ▸ | CDC25B | P30305 | 7/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.36 |
| ▸ | CDC25A | P30304 | 3/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008260 | 1.00 | PTPN1 (0.36) | PTPN1CDC25BPTPN2CDC25APTPN6 | |
| SCHEMBL17227496 | 1.00 | PTPN1 (0.36) | PTPN1CDC25BPTPN2CDC25APTPN6 | |
| SCHEMBL14376675 | 0.91 | PTPN1 (0.36) | PTPN1CDC25BPTPN2CDC25APTPN6 | |
| SCHEMBL2002735 | 0.90 | ANPEP (0.35) | PTPN1CDC25BPTPN2CDC25APTPN6 | |
| SCHEMBL26263865 | 0.90 | ANPEP (0.35) | PTPN1CDC25BPTPN2CDC25APTPN6 | |
| SCHEMBL15501143 | 0.88 | ANPEP (0.38) | ANPEP | |
| SCHEMBL2003090 | 0.88 | ANPEP (0.38) | ANPEP | |
| SCHEMBL2003089 | 0.88 | ANPEP (0.38) | ANPEP | |
| SCHEMBL14376674 | 0.87 | BTN3A1 (0.35) | PTPN1CDC25BPTPN2CDC25APTPN6 | |
| SCHEMBL25401991 | 0.83 | ANPEP (0.31) | ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521762-B1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7960523-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080033155-A1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-7288640-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-7232900-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | CORIXA CORPORATION (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2006012425-A2 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040267007-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | CORIXA CORPORATION | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267007-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | DDOST, STT3A, STT3B | PTPN1 2351/4885CDC25B 2644/4885PTPN2 2183/4885 |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | DDOST, AGL, GALE | PTPN1 2254/4885CDC25B 2860/4885PTPN2 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.